FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Financial Statements and Exhibits

FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

Story continues below


FIBROGEN INC Exhibit
EX-99.1 2 d474823dex991.htm EX-99.1 EX-99.1 Exhibit 99.1      NEWS RELEASE     FIBROGEN ANNOUNCES ACCEPTANCE BY CHINA FDA OF ROXADUSTAT NEW DRUG APPLICATION (NDA) FOR TREATMENT OF ANEMIA ASSOCIATED WITH DIALYSIS AND NON-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) Triggers Milestone Payment of $15 Million by AstraZeneca SAN FRANCISCO,…
To view the full exhibit click here

About FibroGen, Inc. (NASDAQ:FGEN)

FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

An ad to help with our costs